

Carbon Reduction Plan

Supplier name: Orion Pharma (UK) Ltd.

Publication date: May 2026

Commitment to achieving Net Zero

Orion Pharma (UK) Ltd. as part of Orion Corporation is committed to achieving net-zero emissions by 2050 for emissions scopes 1, 2 and 3.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2023	
Additional Details relating to the Baseline Emissions calculations.	
The greenhouse gas emissions information provided in this CRP consists of the global, parent company level emissions. Orion will further develop its climate reporting capabilities and explore options to provide emissions information of Orion Pharma (UK) Ltd. in future CRP submissions.	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	5,511
Scope 2	8,429 (market-based method, preferred) 11,726 (location-based method)
Scope 3 (Included Sources)	417,455 Including the following emissions categories: <ol style="list-style-type: none"> 1. Purchased goods and services 2. Capital goods 3. Fuel and energy- related activities 4. Upstream transportation and distribution 5. Waste generated in operations 6. Business travel 7. Employee commuting 8. Upstream leased assets 9. Downstream transportation and distribution 10. Processing of sold products 11. Use of sold products 12. End-of-life treatment of sold products 13. Downstream leased assets

Total Emissions	431,395 (market-based method, preferred) 434,692 (location-based method)
------------------------	---

Current Emissions Reporting

Reporting Year: 2025	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	5,018
Scope 2	4,557 (market-based method, preferred) 6,776 (location-based method)
Scope 3 (Included Sources)	403,909 Including the following emissions categories: <ol style="list-style-type: none"> 1. Purchased goods and services 2. Capital goods 3. Fuel and energy- related activities 4. Upstream transportation and distribution 5. Waste generated in operations 6. Business travel 7. Employee commuting 8. Upstream leased assets 9. Downstream transportation and distribution 10. Processing of sold products 11. Use of sold products 12. End-of-life treatment of sold products 13. Downstream leased assets
Total Emissions	413,483 (market-based method, preferred) 415,702 (location-based method)

Emissions reduction targets

To continue our progress towards achieving net-zero emissions by 2050, we have also established interim emission reduction targets. These targets are set at the parent-company level and align with Orion Pharma (UK) Ltd. Our most important interim targets are our approved near-term science-based targets, which are as follows:

- Orion commits to reduce absolute scope 1 and 2 GHG emissions 70% by 2030 from a 2023 base year.
- Orion also commits that 78% of its suppliers by emissions covering purchased goods and services, capital goods and upstream transportation and distribution will have science-based targets by 2029.

We are developing emission reduction targets going beyond 2030 and look forward to sharing our targets in future CRP submissions.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives:

We continue to systematically implement measures meant to promote energy efficiency, and reduce our consumption of energy and overall, our GHG emissions. Below are listed various completed carbon reduction initiatives and highlights from the previous year. These include those with Orion Pharma (UK) Ltd. relevance, in addition to Orion Corporation.

- In 2025, we continued progress towards our near-term science-based targets, as our combined absolute Scope 1 and 2 emissions decreased by 13%. Compared to the 2023 baseline, our cumulative emissions have now decreased by 31%.
- Suppliers and partners are required to commit to Orion's Third Party Code of Conduct. Orion's Third Party Code of Conduct includes environmental criteria, which requires the Third Party to monitor and reduce its GHG emissions. By the end of 2025, 96% of Orion's active suppliers measured by spend confirmed their adherence to the Third Party Code of Conduct.
- Orion has conducted product level life cycle assessments for its dry powder inhalers¹. Orion's dry powder inhalers are sold worldwide, including by Orion Pharma (UK) Ltd. in the UK. Based on these assessments Orion has built an understanding of the environmental impact of own manufacturing and identified where reduction efforts should be focused on our way to net-zero.
- Encouraging agile working and environmentally friendly traveling options, including commuting and business travel.
- Create awareness and promote an environmental culture within the organisation enabling employees to take the environment into consideration in their day-to-day.

In the future we hope to implement further measures such as:

- At the group level, we have greatly improved our emission calculations, especially in our Scope 3 accounting. This enables us to better identify targeted opportunities for further emission reductions in our value chain.
- Carbon neutral employee commuting and business travel within the UK.

Most of Orion's own emissions (Scope 1 and 2) are generated in manufacturing sites. All of Orion's manufacturing sites are located outside the UK. More large-scale investments are systematically made at the group-level to improve our environmental performance of these manufacturing sites. Measures include, for example, electrifying processes and heating and cooling via heat pumps. More information is available at Orion's website².

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.


Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard³ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting⁴.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard⁵.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors of Orion Pharma (UK) Ltd.

Signed on behalf of the Supplier:

Signed by:
René Lindell

 Signer Name: René Lindell
Signing Reason: I approve this document
Signing Time: 06-May-2026 | 3:47 PM EEDT

6055C5A71C284FDEA69784C85F046D08

Signed by:
Mikko Kempainen

 Signer Name: Mikko Kempainen
Signing Reason: I approve this document
Signing Time: 08-May-2026 | 9:54 AM EEDT

B5FA2525E39F4CFAB09FAACD0A29840E

¹ <https://www.orion.fi/en/sustainability/environment/environmental-impacts-of-operations/carbon-footprint-assessment-of-orions-dry-powder-inhalers/>

² <https://www.orion.fi/en/sustainability/>

³ <https://ghgprotocol.org/corporate-standard>

⁴ <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

⁵ <https://ghgprotocol.org/standards/scope-3-standard>